Biogen (XSWX:BIIB) Other Current Liabilities : CHF781 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biogen Other Current Liabilities?

Biogen's other current liabilities for the quarter that ended in Mar. 2024 was CHF781 Mil.

Biogen's quarterly other current liabilities increased from Sep. 2023 (CHF249 Mil) to Dec. 2023 (CHF1,015 Mil) but then declined from Dec. 2023 (CHF1,015 Mil) to Mar. 2024 (CHF781 Mil).

Biogen's annual other current liabilities increased from Dec. 2021 (CHF318 Mil) to Dec. 2022 (CHF1,064 Mil) but then declined from Dec. 2022 (CHF1,064 Mil) to Dec. 2023 (CHF1,015 Mil).

Biogen Other Current Liabilities Historical Data

The historical data trend for Biogen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Current Liabilities Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Biogen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Biogen Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (XSWX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.